Advertisement

World Journal of Urology

, Volume 35, Issue 2, pp 261–270 | Cite as

Prognostic value of preoperative NLR, dNLR, PLR and CRP in surgical renal cell carcinoma patients

  • Hong Hu
  • Xiajuan Yao
  • Xiangcheng Xie
  • Xia Wu
  • Chuanming Zheng
  • Wenkai XiaEmail author
  • Shenglin MaEmail author
Original Article

Abstract

Background

Emerging evidences indicate that inflammation plays a crucial role in carcinogenesis and tumor progression. Inflammatory response biomarkers are recognized as promising prognostic factors for improving predictive accuracy in renal cell carcinoma (RCC). We aimed to evaluate the prognostic significance of preoperative neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR) and serum C-reactive protein (CRP) in RCC.

Methods

484 surgical RCC patients were enrolled from 2006 to 2010 in this study. Receiver operating curve (ROC) was applied to assess the optimal cutoff levels for four biomarkers, and the prognostic values were determined by Kaplan–Meier curve, univariate and multivariate COX regression models. The predictive accuracy was evaluated by concordance index (c-index).

Results

The median follow-up duration after surgical resection was 36 months. The optimal cutoff levels were 2.78 for NLR, 2.05 for dNLR, 185 for PLR and 5.1 for CRP by ROC curves analysis. Elevated NLR, dNLR, PLR and CRP were significantly correlated with worse overall survival (OS). Multivariate analysis showed that elevated NLR was an independent risk factor for OS, and NLR was superior to dNLR, PLR and CRP based on hazard ratio (HR 2.10, 95 % CI 1.21–3.64, P = 0.008). Additionally, the nomogram could more effectively work in predicting OS (c-index: 0.749) in surgical RCC patients.

Conclusion

Pre-operation NLR can be considered as a potential prognostic biomarker in patients with RCC who underwent surgical resection.

Keywords

Neutrophil-to-lymphocyte ratio Renal cell carcinoma Survival Prognosis 

Notes

Authors’ contribution

MA and XIE developed the protocol; XIA, YAO and ZHENG collected the data; WU and XIA analyzed the data; HU and XIA wrote and edited the manuscript; and HU supervised the project.

Compliance with ethical standards

Conflict of interest

None.

Ethical standards

The study was approved by Medical Ethics Committee of Jiangyin People’s Hospital, Hangzhou First People’s Hospital and Zhejiang Cancer Hospital, respectively.

References

  1. 1.
    Lipworth L, Tarone RE, McLaughlin JK (2011) Renal cell cancer among African Americans: an epidemiologic review. BMC Cancer 11:133. doi: 10.1186/1471-2407-11-133 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Chow WH, Dong LM, Devesa SS (2010) Epidemiology and risk factors for kidney cancer. Nat Rev Urol 7(5):245–257. doi: 10.1038/nrurol.2010.46 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Kim SP, Shah ND, Weight CJ, Thompson RH, Moriarty JP, Shippee ND et al (2011) Contemporary trends in nephrectomy for renal cell carcinoma in the United States: results from a population based cohort. J Urol 186(5):1779–1785. doi: 10.1016/j.juro.2011.07.041 CrossRefPubMedGoogle Scholar
  4. 4.
    Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436–444. doi: 10.1038/nature07205 CrossRefPubMedGoogle Scholar
  5. 5.
    Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA (2013) Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 13(11):759–771. doi: 10.1038/nrc3611 CrossRefPubMedGoogle Scholar
  6. 6.
    Fox P, Hudson M, Brown C, Lord S, Gebski V, De Souza P et al (2013) Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. Br J Cancer 109(1):147–153. doi: 10.1038/bjc.2013.300 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357(9255):539–545. doi: 10.1016/S0140-6736(00)04046-0 CrossRefPubMedGoogle Scholar
  8. 8.
    Deng Q, He B, Liu X, Yue J, Ying H, Pan Y et al (2015) Prognostic value of pre-operative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive model. J Transl Med 13:66. doi: 10.1186/s12967-015-0409-0 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Halazun KJ, Aldoori A, Malik HZ, Al-Mukhtar A, Prasad KR, Toogood GJ et al (2008) Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol 34(1):55–60. doi: 10.1016/j.ejso.2007.02.014 CrossRefPubMedGoogle Scholar
  10. 10.
    Al Murri AM, Wilson C, Lannigan A, Doughty JC, Angerson WJ, McArdle CS et al (2007) Evaluation of the relationship between the systemic inflammatory response and cancer-specific survival in patients with primary operable breast cancer. Br J Cancer 96(6):891–895. doi: 10.1038/sj.bjc.6603682 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, Friesenbichler J et al (2014) The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. Int J Cancer 135(2):362–370. doi: 10.1002/ijc.28677 CrossRefPubMedGoogle Scholar
  12. 12.
    Jamieson NB, Glen P, McMillan DC, McKay CJ, Foulis AK, Carter R et al (2005) Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br J Cancer 92(1):21–23. doi: 10.1038/sj.bjc.6602305 CrossRefPubMedGoogle Scholar
  13. 13.
    Steffens S, Kohler A, Rudolph R, Eggers H, Seidel C, Janssen M et al (2012) Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients. BMC Cancer 12:399. doi: 10.1186/1471-2407-12-399 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Lamb GW, Aitchison M, Ramsey S, Housley SL, McMillan DC (2012) Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems. Br J Cancer 106(2):279–283. doi: 10.1038/bjc.2011.556 CrossRefPubMedGoogle Scholar
  15. 15.
    Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17(6):1471–1474. doi: 10.1245/s10434-010-0985-4 CrossRefPubMedGoogle Scholar
  16. 16.
    Letang N, Cabaniols L, Pouessel D, Robert M, Iborra F, Culine S et al (2009) Prognostic factors in renal cell carcinoma. Bull Cancer 96(4):475–484. doi: 10.1684/bdc.2009.0845 PubMedGoogle Scholar
  17. 17.
    Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ (2012) A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 107(4):695–699. doi: 10.1038/bjc.2012.292 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Yasuda Y, Saito K, Yuasa T, Kitsukawa S, Urakami S, Yamamoto S et al (2013) Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Int J Clin Oncol 18(5):884–889. doi: 10.1007/s10147-012-0454-0 CrossRefPubMedGoogle Scholar
  19. 19.
    Park YH, Ku JH, Kwak C, Kim HH (2014) Post-treatment neutrophil-to-lymphocyte ratio in predicting prognosis in patients with metastatic clear cell renal cell carcinoma receiving sunitinib as first line therapy. Springerplus 3:243. doi: 10.1186/2193-1801-3-243 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Koh YW, Park CS, Yoon DH, Suh C, Huh J (2014) Should the cut-off values of the lymphocyte to monocyte ratio for prediction of prognosis in diffuse large B-cell lymphoma be changed in elderly patients? Eur J Haematol 93(4):340–348. doi: 10.1111/ejh.12354 CrossRefPubMedGoogle Scholar
  21. 21.
    Muller I, Munder M, Kropf P, Hansch GM (2009) Polymorphonuclear neutrophils and T lymphocytes: strange bedfellows or brothers in arms? Trends Immunol 30(11):522–530. doi: 10.1016/j.it.2009.07.007 CrossRefPubMedGoogle Scholar
  22. 22.
    Kuper H, Adami HO, Trichopoulos D (2000) Infections as a major preventable cause of human cancer. J Intern Med 248(3):171–183CrossRefPubMedGoogle Scholar
  23. 23.
    Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT et al (2009) Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 58(1):15–23. doi: 10.1007/s00262-008-0516-3 CrossRefPubMedGoogle Scholar
  24. 24.
    Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH (2003) Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 6(4):283–287. doi: 10.1023/B:AGEN.0000029415.62384.ba CrossRefPubMedGoogle Scholar
  25. 25.
    Manola J, Royston P, Elson P, McCormack JB, Mazumdar M, Negrier S et al (2011) Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res 17(16):5443–5450. doi: 10.1158/1078-0432.CCR-11-0553 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Diamond E, Riches J, Faltas B, Tagawa ST, Nanus DM (2014) Immunologics and chemotherapeutics for renal cell carcinoma. Semin Intervent Radiol 31(1):91–97. doi: 10.1055/s-0033-1363848 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Gerber HP, Olazoglu E, Grewal IS (2010) Targeting inflammatory cells to improve anti-VEGF therapies in oncology. Recent Results Cancer Res 180:185–200. doi: 10.1007/978-3-540-78281-0_11 CrossRefPubMedGoogle Scholar
  28. 28.
    Scholl SM, Pallud C, Beuvon F, Hacene K, Stanley ER, Rohrschneider L et al (1994) Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst 86(2):120–126CrossRefPubMedGoogle Scholar
  29. 29.
    Menges T, Engel J, Welters I, Wagner RM, Little S, Ruwoldt R et al (1999) Changes in blood lymphocyte populations after multiple trauma: association with posttraumatic complications. Crit Care Med 27(4):733–740CrossRefPubMedGoogle Scholar
  30. 30.
    Dalpiaz O, Pichler M, Mannweiler S, Martin Hernandez JM, Stojakovic T, Pummer K et al (2014) Validation of the pretreatment derived neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma. Br J Cancer 110(10):2531–2536. doi: 10.1038/bjc.2014.180 CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Solomon P, O’Brien K, Wilkins S, Gervais N (2014) Aging with HIV and disability: the role of uncertainty. AIDS Care 26(2):240–245. doi: 10.1080/09540121.2013.811209 CrossRefPubMedGoogle Scholar
  32. 32.
    Oh BS, Jang JW, Kwon JH, You CR, Chung KW, Kay CS et al (2013) Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. BMC Cancer 13:78. doi: 10.1186/1471-2407-13-78 CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Mantovani A, Schioppa T, Porta C, Allavena P, Sica A (2006) Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 25(3):315–322. doi: 10.1007/s10555-006-9001-7 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  1. 1.Department of NephrologyThe Affiliated Jiangyin Hospital of Southeast University Medical CollegeJiangyinChina
  2. 2.Department of Nephrology, Hangzhou First People’s HospitalHangzhou Hospital Affiliated to Nanjing Medical UniversityHangzhouChina
  3. 3.Department of Head and Neck SurgeryZhejiang Cancer HospitalHangzhouChina
  4. 4.Department of Oncology, Hangzhou First People’s HospitalHangzhou Hospital Affiliated to Nanjing Medical UniversityHangzhouChina

Personalised recommendations